頭孢菌素類藥物市場：依代、類型、劑型、適應症、通路及地區分類。

預計到2026年，頭孢菌素類藥物市場規模將達218.7億美元，2033年將達到236.5億美元。 2026年至2033年期間的複合年成長率預計為3.76%。

頭孢菌素是一類頻譜半合成BETA-內醯胺類抗生素，常用於治療細菌感染疾病，如細菌性腦膜炎、中耳炎、肺炎、結核病、上呼吸道感染疾病、眼部感染、鼻竇炎、尿道感染感染疾病、皮膚感染疾病和性行為感染感染。最常用的頭孢菌素包括頭孢氨芐、頭孢曲松、頭孢克肟、頭孢地尼和頭孢克洛。在撒哈拉以南非洲國家，例如衣索比亞、加納、奈及利亞和塞內加爾，由於醫療設施和基礎設施落後，細菌感染疾病十分普遍，因此頭孢菌素市場具有巨大的潛力。例如，根據世界衛生組織（世衛組織）2018年2月的報告，從西部的塞內加爾到東部的衣索比亞，撒哈拉以南非洲地區的細菌感染負擔最為沉重。該地區每年仍有約3萬例細菌感染病例報告。

市場動態

全球呼吸道感染疾病發病率的上升預計將推動頭孢菌素類藥物市場的成長。例如，根據2017年《全球呼吸道疾病影響》報告，下呼吸道感染疾病和肺炎是兩大主要死因，每年造成超過400萬人死亡。此外，2015年，肺炎導致920,136名五歲以下兒童死亡，佔該年齡層所有死亡人數的15%。肺炎鏈球菌仍是肺炎最常見的致病菌，2015年導致393,000名五歲以下兒童死亡。

然而，美國食品藥物管理局（FDA）召回次數的增加等因素正在阻礙頭孢菌素類藥物市場的成長。例如，2019年6月，魯賓有限公司（Lupin Limited）從美國市場召回了18,604瓶（60毫升）用於治療細菌感染疾病的頭孢地尼（頭孢菌素）口服懸浮液。此外，該公司於2019年1月宣布，由於違反現行藥品生產品質管理規範（CGMP），在美國召回了287,784瓶頭孢地尼口服懸浮液。

本次調查的主要特點。

• 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數提供全球頭孢菌素藥物市場主要企業的概況：公司概況、財務表現、產品系列、地理分佈、分銷策略、主要發展和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、政府舉措、技術升級、市場擴張和行銷策略做出明智的決策。
• 本報告旨在為行業內的各種相關人員提供參考，包括頭孢菌素藥物市場的投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 阻礙因素
• PEST分析
• 波特五力分析
• 市場機遇
• 法規環境
• 主要進展
• 產業趨勢

第4章 全球頭孢菌素類藥物市場：按代分類，2026-2033年

• 第一代頭孢菌素
• 第二代頭孢菌素
• 第三代頭孢菌素
• 第四代頭孢菌素
• 第五代頭孢菌素

第5章 全球頭孢菌素類藥物市場：按類型分類，2026-2033年

• 品牌
• 非專利的

第6章 全球頭孢菌素類藥物市場：以劑型分類，2026-2033年

• 口服藥物
• 藥片
• 膠囊
• 液體
• 注射藥物

第7章 全球頭孢菌素類藥物市場：依適應症分類，2026-2033年

• 呼吸道感染疾病
• 皮膚感染疾病
• 耳部感染疾病
• 細菌感染疾病
• 尿道感染
• 性行為感染傳染病
• 鼻竇炎
• 手術預防
• 其他
• 腦膜炎
• 急腹症
• 骨盆腔感染疾病

第8章 全球頭孢菌素類藥物市場：依分銷管道分類，2026-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 全球頭孢菌素類藥物市場：依地區分類，2026-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• 熱圖分析
  • Market Share Analysis（3x3 Matrix）
  • 公司簡介
  • Merck &Co. Inc.
• GlaxoSmithKline Plc
  • Pfizer Inc.
• Allergan plc.
  • Abbott Laboratories
• Basilea Pharmaceutica Ltd.
  • Sanofi SA
• 羅氏製藥
  • Lupin Limited
• 梯瓦製藥工業公司
  • B. Braun Melsungen AG.

第11章 分析師建議

• 機會
• 分析師意見
• Coherent Opportunity Map

第12章

• 參考
• 調查方法

Cephalosporin Drugs Market is estimated to be valued at USD 21.87 Bn in 2026 and is expected to reach USD 23.65 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.76% 2025 To 2032 from 2026 to 2033.

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.

Market Dynamics

Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.

However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

Key features of the study

• This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2026, considering 2018 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• By Generation
  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin
• By Type
  • Branded Cephalosporin Drugs
  • Generic Cephalosporin Drugs
• By Formulation
  • Oral
  • Tablets
  • Capsules
  • Liquid
  • Injection
• By Indication
  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Bacterial Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Sinus Infection
  • Surgical Prophylaxis
  • Others
  • Meningitis
  • Acute Abdomen Infection
  • Pelvic infection
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Merck & Co. Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Allergan plc.
  • Abbott Laboratories
  • Basilea Pharmaceutica Ltd.
  • Sanofi S.A.
  • Hoffmann-La Roche AG
  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Braun Melsungen AG.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Generation
  • Market Snippet, By Type
  • Market Snippet, By Formulation
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• PEST Analysis
• PORTER's Five Forces Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Cephalosporin Drugs Market, By Generation, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• First-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Second-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Third-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Fourth-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Fifth-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Cephalosporin Drugs Market, By Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Branded Cephalosporin Drugs
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Generic Cephalosporin Drugs
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Cephalosporin Drugs Market, By Formulation, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tablets
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Capsules
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Liquid
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Injection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Cephalosporin Drugs Market, By Indication, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Respiratory Tract Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Skin Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Ear Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Bacterial Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Urinary Tract Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Sexually Transmitted Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Sinus Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Surgical Prophylaxis
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Meningitis
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Acute Abdomen Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pelvic Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

8. Global Cephalosporin Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Online Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

9. Global Cephalosporin Drugs Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
  • Merck & Co. Inc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• GlaxoSmithKline plc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Pfizer Inc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Allergan plc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Abbott Laboratories
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Basilea Pharmaceutica Ltd.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Sanofi S.A.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• F. Hoffmann-La Roche AG
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Lupin Limited
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • B. Braun Melsungen AG.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates

11. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Section

• References
• Research Methodology
• About Us and Sales Contact